Navegar

Colección

Datos Estadísticas

Artículo

Colado, A.; Genoula, M.; Cougoule, C.; Marín Franco, J.L.; Almejún, M.B.; Risnik, D.; Kviatcovsky, D.; Podaza, E.; Elías, E.E.; Fuentes, F.; Maridonneau-Parini, I.; Bezares, F.R.; Fernandez Grecco, H.; Cabrejo, M.; Jancic, C.; Sasiain, M.C.; Giordano, M.; Gamberale, R. (...) Borge, M. "Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis" (2018) Blood Cancer Journal. 8(11)
Estamos trabajando para incorporar este artículo al repositorio
Consulte el artículo en la página del editor
Consulte la política de Acceso Abierto del editor

Registro:

Documento: Artículo
Título:Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis
Autor:Colado, A.; Genoula, M.; Cougoule, C.; Marín Franco, J.L.; Almejún, M.B.; Risnik, D.; Kviatcovsky, D.; Podaza, E.; Elías, E.E.; Fuentes, F.; Maridonneau-Parini, I.; Bezares, F.R.; Fernandez Grecco, H.; Cabrejo, M.; Jancic, C.; Sasiain, M.C.; Giordano, M.; Gamberale, R.; Balboa, L.; Borge, M.
Filiación:Laboratorio de Inmunología Oncológica, Instituto de Medicina Experimental (IMEX)-CONICET-Academia Nacional de Medicina (ANM), CABA, Argentina
Laboratorio de Inmunología de Enfermedades Respiratorias, IMEX-CONICET-ANM, CABA, Argentina
International Associated Laboratory (LIA) CNRS/CONICET “IM-TB/HIV” (1167), Toulouse, France
International Associated Laboratory (LIA) CNRS/CONICET “IM-TB/HIV” (1167), Buenos Aires, Argentina
Institut de Pharmacologie et de Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France
Departamento de Fisiología, Biología Molecular y Celular, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, CABA, Argentina
IMEX-CONICET-ANM, CABA, Argentina
Sección de Hematología, Hospital General de Agudos Dr. Teodoro Álvarez, CABA, Argentina
Departamento de Hematología, Sanatorio Julio Méndez, CABA, Argentina
Laboratorio de Inmunidad Innata, MEX-CONICET-ANM, CABA, Argentina
Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, CABA, Argentina
Palabras clave:colony stimulating factor 1; ibrutinib; interleukin 10; interleukin 4; cancer patient; chronic lymphatic leukemia; disease association; drug efficacy; gamma delta T lymphocyte; glucose intake; human; immune response; incidence; infection risk; Letter; macrophage; Mycobacterium tuberculosis; natural killer cell; nonhuman; phagocytosis; protein phosphorylation; treatment response; world health organization
Año:2018
Volumen:8
Número:11
DOI: http://dx.doi.org/10.1038/s41408-018-0136-x
Título revista:Blood Cancer Journal
Título revista abreviado:Blood Cancer J.
ISSN:20445385
CAS:colony stimulating factor 1, 81627-83-0; ibrutinib, 936563-96-1
Registro:https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_20445385_v8_n11_p_Colado

Referencias:

  • Dubovsky, J.A., Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes (2013) Blood, 122, pp. 2539-2549. , COI: 1:CAS:528:DC%2BC3sXhs1CgsrfK
  • Fiorcari, S., Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia (2016) Oncotarget, 7, pp. 65968-65981
  • Da Roit, F., Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy (2015) Haematologica, 100, pp. 77-86
  • Chen, Z.W., Immune regulation of gammadelta T cell responses in mycobacterial infections (2005) Clin. Immunol., 116, pp. 202-207. , COI: 1:CAS:528:DC%2BD2MXns1Wgu7w%3D
  • Verreck, F.A., Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria (2004) Proc. Natl Acad. Sci. USA, 101, pp. 4560-4565. , COI: 1:CAS:528:DC%2BD2cXjtFKis70%3D
  • Cougoule, C., Blood leukocytes and macrophages of various phenotypes have distinct abilities to form podosomes and to migrate in 3D environments (2012) Eur. J. Cell Biol., 91, pp. 938-949. , COI: 1:CAS:528:DC%2BC38XhtlKrsbbL
  • Tan, Z., Pyruvate dehydrogenase kinase 1 participates in macrophage polarization via regulating glucose metabolism (2015) J. Immunol., 194, pp. 6082-6089. , COI: 1:CAS:528:DC%2BC2MXpsFOmu70%3D
  • Sun, C., Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib (2015) Blood, 126, pp. 2213-2219. , COI: 1:CAS:528:DC%2BC28XjvV2rtLo%3D
  • Williams, A.M., Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies (2018) Leuk. Lymphoma, 59, pp. 625-632
  • Itchaki, G., Brown, J.R., Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia (2018) Ther. Adv. Hematol., 9, pp. 3-19. , COI: 1:CAS:528:DC%2BC1cXhvVSmsbw%3D
  • Yin, Q., Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia (2017) J. Immunol., 198, pp. 1740-1747. , COI: 1:CAS:528:DC%2BC2sXitFWlurk%3D
  • Cubillos-Zapata, C., Ibrutinib as an antitumor immunomodulator in patients with refractory chronic lymphocytic leukemia (2016) Oncoimmunology, 5
  • Chamilos, G., Lionakis, M.S., Kontoyiannis, D.P., Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways (2018) Clin. Infect. Dis., 66, pp. 140-148
  • Wang, S.Y., Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia (2015) Ann. Hematol., 94, pp. 1419-1420
  • Ahn, I.E., Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib (2016) Blood, 128, pp. 1940-1943. , COI: 1:CAS:528:DC%2BC2sXhtlSitr4%3D

Citas:

---------- APA ----------
Colado, A., Genoula, M., Cougoule, C., Marín Franco, J.L., Almejún, M.B., Risnik, D., Kviatcovsky, D.,..., Borge, M. (2018) . Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis. Blood Cancer Journal, 8(11).
http://dx.doi.org/10.1038/s41408-018-0136-x
---------- CHICAGO ----------
Colado, A., Genoula, M., Cougoule, C., Marín Franco, J.L., Almejún, M.B., Risnik, D., et al. "Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis" . Blood Cancer Journal 8, no. 11 (2018).
http://dx.doi.org/10.1038/s41408-018-0136-x
---------- MLA ----------
Colado, A., Genoula, M., Cougoule, C., Marín Franco, J.L., Almejún, M.B., Risnik, D., et al. "Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis" . Blood Cancer Journal, vol. 8, no. 11, 2018.
http://dx.doi.org/10.1038/s41408-018-0136-x
---------- VANCOUVER ----------
Colado, A., Genoula, M., Cougoule, C., Marín Franco, J.L., Almejún, M.B., Risnik, D., et al. Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis. Blood Cancer J. 2018;8(11).
http://dx.doi.org/10.1038/s41408-018-0136-x